GENE ONLINE|News &
Opinion
Blog

2022-08-01| Special

BIO 2022: Options for Raising Capital in a Down Market

by Richard Chau
Share To
From left to right: Celia Economides (Moderator), Igor DaCruz, Cecilia Gonzalo, Marshall Urist, MD, PhD

The current stock market environment for small biotechs is tough even by historical standards. Many biotechs are now trading below cash value and IPOs have slowed significantly. In the current environment, companies are having to consider alternative methods for raising capital to advance clinical trials and R&D pipelines.

In a panel discussion at the 2022 BIO International Convention (BIO2022), experts in biotech investment and capital management covered some of these specialized financing mechanisms, such as private investments in public entities (PIPEs), royalty deals, and other structured deals that use pipelines as collateral. Moderated by Celia Economides, Executive Vice President and Chief Financial Officer at Gritstone Bio, the session included:
Igor DaCruz, Managing Director at Runway Growth Capital
Cecilia Gonzalo, Partner at Oberland Capital Management
Marshall Urist, MD, PhD, Executive Vice President and Head of Research & Investment of Royalty Pharma Management, LLC

It's free! Log in now to read

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top